1800-272-662
Shopping Cart 0
countryflagAU
Login

Evolus Inc

Healthcare US EOLS

5.01USD
0.10(2.04%)

Last update at 2026-03-13T20:00:00Z

Day Range

4.835.03
LowHigh

52 Week Range

7.0715.43
LowHigh

Fundamentals

  • Previous Close 4.91
  • Market Cap790.77M
  • Volume936525
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-27.71900M
  • Revenue TTM219.70M
  • Revenue Per Share TTM3.82
  • Gross Profit TTM 92.73M
  • Diluted EPS TTM-1.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -74.31700M -46.76800M -162.93600M -105.06100M -46.80200M
Minority interest - - - - -
Net income -74.41200M -46.81000M -163.01300M -90.03400M -46.86700M
Selling general administrative 147.59M 118.36M 98.19M 113.59M 29.15M
Selling and marketing expenses - - - - -
Gross profit 92.73M 56.14M 38.24M 26.91M 0.00000M
Reconciled depreciation 4.50M 6.31M 7.68M 5.00M 0.00900M
Ebit -57.57500M -63.61500M -68.69800M -94.78700M -45.93900M
Ebitda -59.49800M -64.28200M -59.02900M -92.97600M -45.93000M
Depreciation and amortization -1.92300M -0.66700M 9.67M 1.81M 0.00900M
Non operating income net other 0.11M -2.36300M -9.86800M -6.11400M -
Operating income -57.57500M -63.61500M -68.69800M -94.78700M -46.14200M
Other operating expenses 206.19M 163.29M 125.24M 129.71M 35.64M
Interest expense 9.10M 1.40M 10.50M 7.95M 0.86M
Tax provision 0.10M 0.04M 0.08M -15.02700M 0.07M
Interest income 0.12M 0.00100M 0.64M 1.84M 0.20M
Net interest income -8.97800M -1.39500M -9.86800M -6.11400M -0.66000M
Extraordinary items - - - - -
Non recurring 2.00M - 86.38M - -
Other items - - - - -
Income tax expense 0.10M 0.04M 0.08M -15.02700M 0.07M
Total revenue 148.62M 99.67M 56.54M 34.92M 0.00000M
Total operating expenses 150.30M 119.75M 106.94M 121.70M 35.64M
Cost of revenue 55.89M 43.53M 18.30M 8.01M 0.00000M
Total other income expense net -16.74200M 16.85M -94.23800M -10.27400M -10.50000M
Discontinued operations - - - - -
Net income from continuing ops -74.41200M -46.81000M -163.01300M -90.03400M -46.86700M
Net income applicable to common shares -74.41200M -46.81000M -163.01300M -90.03400M -46.86700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 189.00M 177.98M 257.48M 209.07M 240.44M
Intangible assets 47.11M 48.60M 50.62M 55.30M 59.64M
Earning assets - - - - -
Other current assets 8.06M 5.58M 11.04M 7.02M 5.33M
Total liab 209.69M 159.48M 175.61M 282.03M 160.99M
Total stockholder equity -20.68900M 18.50M -422.88200M -376.07200M -213.05900M
Deferred long term liab - - - 0.03M -
Other current liab 31.61M 2.45M 42.37M 72.89M 17.44M
Common stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Capital stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Retained earnings -558.97900M -497.29400M -422.88200M -376.07200M -213.05900M
Other liab - 39.87M 44.47M 58.12M 59.15M
Good will 21.21M 21.21M 21.21M 21.21M 21.21M
Other assets 0.00000M 2.81M 32.54M 3.65M 2.43M
Cash 62.84M 53.92M 146.26M 102.56M 109.89M
Cash and equivalents - - - - -
Total current liabilities 48.29M 46.51M 57.66M 180.25M 24.44M
Current deferred revenue 11.03M 9.01M 7.93M 3.08M -
Net debt 63.71M 19.28M -71.51300M 35.76M -13.34600M
Short term debt 1.38M 1.32M 1.26M 94.66M 1.20M
Short long term debt - - - 93.45M -
Short long term debt total 126.55M 73.20M 74.74M 138.32M 96.55M
Other stockholder equity 538.72M 516.13M -0.00100M -0.00100M -0.00700M
Property plant equipment - 2.62M 1.37M 4.71M 4.97M
Total current assets 112.42M 100.80M 178.80M 127.61M 152.20M
Long term investments - - - - -
Net tangible assets - -51.30600M 10.04M -149.46300M -1.38900M
Short term investments - - 146.26M 5.00M 19.91M
Net receivables 30.53M 22.45M 14.66M 9.68M 10.66M
Long term debt 120.36M 71.88M 71.22M 40.51M 91.45M
Inventory 11.00M 18.85M 1.76M 3.35M 6.41M
Accounts payable 4.27M 33.73M 6.09M 9.62M 5.80M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.42700M -0.33700M - - 0.00600M
Additional paid in capital - - - - -
Common stock total equity - 0.00100M 0.00100M 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -497.29400M -422.88200M -376.07200M -213.05900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.41M 2.81M 2.76M 0.24M 2.43M
Deferred long term asset charges - - - - -
Non current assets total 76.58M 77.18M 78.68M 81.46M 88.25M
Capital lease obligations 6.19M 2.54M 3.52M 4.36M 5.09M
Long term debt total - 71.88M 71.22M - 91.45M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.93900M 5.00M 12.19M -18.86700M -0.00900M
Change to liabilities -4.23100M 20.10M 2.32M -2.55900M 4.01M
Total cashflows from investing activities -2.93900M 4.03M 12.19M -23.43400M -0.00900M
Net borrowings -0.50000M -27.62800M 39.48M 70.66M -3.87300M
Total cash from financing activities -1.51600M 73.05M 38.35M 133.55M 118.84M
Change to operating activities -15.14200M -2.21100M 29.82M -5.46000M 1.52M
Net income -74.41200M -46.81000M -163.01300M -90.03400M -46.86700M
Change in cash -11.65000M 43.69M -7.33000M 16.73M 93.16M
Begin period cash flow 65.57M 102.56M 109.89M 93.16M 0.00000M
End period cash flow 53.92M 146.26M 102.56M 109.89M 93.16M
Total cash from operating activities -8.77400M -33.38800M -57.87100M -93.38300M -25.66700M
Issuance of capital stock 0.00000M 103.34M 0.00000M 73.31M 124.01M
Depreciation 4.50M 6.31M 7.68M 5.00M 0.00900M
Other cashflows from investing activities -1.32100M -0.57700M -2.32300M -4.22200M -
Dividends paid - - - - -
Change to inventory -10.68800M -2.97900M 4.54M -4.48200M -4.48200M
Change to account receivables -9.38900M -5.56600M -1.08500M -11.04800M -11.04800M
Sale purchase of stock - 103.12M - 73.11M 122.97M
Other cashflows from financing activities -2.05500M 66.04M 38.87M 61.28M -0.17200M
Change to netincome 18.17M 17.44M 59.17M -0.99000M 17.54M
Capital expenditures 2.94M 0.97M 3.14M 4.57M 0.00900M
Change receivables -9.38900M -5.56600M -1.08500M -11.04800M -
Cash flows other operating -9.16800M -22.41000M 83.15M 10.48M -0.35300M
Exchange rate changes - - - - -
Cash and cash equivalents changes -91.99700M 43.69M -7.33000M 16.73M 93.16M
Change in working capital -34.25100M -11.54300M 35.60M -20.80700M 2.79M
Stock based compensation 10.83M 9.58M 10.58M 9.52M 6.97M
Other non cash items 84.58M 9.06M 51.25M 17.99M 11.36M
Free cash flow -11.71300M -34.35800M -61.00900M -97.95000M -25.67600M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EOLS
Evolus Inc		 0.10 2.04% 5.01 - - 3.68 17.05 3.99 -19.3067
ZTS
Zoetis Inc		 0.16 0.14% 115.62 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.51 2.02% 24.74 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 124.91 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 - -% 17.77 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus Inc

520 Newport Center Drive, Newport Beach, CA, United States, 92660

Key Executives

Name Title Year Born
Mr. David Moatazedi Pres, CEO & Director 1978
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. Chief Medical Officer and Head of R&D 1962
Ms. Sandra Beaver Chief Financial Officer NA
Mr. David K. Erickson VP of Investor Relations NA
Mr. Jeffrey J. Plumer Gen. Counsel NA
Mr. Kurt Knab VP of Sales NA
Ms. Crystal Muilenburg Chief Marketing Officer 1980
Ms. Jessica Novak Sr. VP of HR NA
Mr. David Moatazedi President, CEO & Director 1978
Ms. Sandra Beaver Chief Financial Officer 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.